JNJ-49095397
CAS No. 1220626-82-3
JNJ-49095397( RV568 | RV-568 | JNJ49095397 )
Catalog No. M10833 CAS No. 1220626-82-3
JNJ-49095397 (RV-568) is a specific narrow-spectrum kinase inhibitor that inhibits a selected set of kinases involved in COPD inflammation with IC50 of 5, 40 and 52 nM for p38α, p38γ and HCK, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 873 | Get Quote |
|
| 50MG | 1782 | Get Quote |
|
| 100MG | 2250 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameJNJ-49095397
-
NoteResearch use only, not for human use.
-
Brief DescriptionJNJ-49095397 (RV-568) is a specific narrow-spectrum kinase inhibitor that inhibits a selected set of kinases involved in COPD inflammation with IC50 of 5, 40 and 52 nM for p38α, p38γ and HCK, respectively.
-
DescriptionJNJ-49095397 (RV-568) is a specific narrow-spectrum kinase inhibitor that inhibits a selected set of kinases involved in COPD inflammation with IC50 of 5, 40 and 52 nM for p38α, p38γ and HCK, respectively; shows potent anti-inflammatory effects in monocytes and macrophages, demonstrates synergistic interaction in poly I:C-stimulated BEAS-2B cells and in the cigarette smoke model combined with corticosteroid.COPD Phase 2 Clinical.
-
In Vitro——
-
In VivoAnimal Model:Nonfasted Balb/c mice, LPS-induced neutrophil accumulation model Dosage:1, 4 and 20 μg/mouse Administration:Intratracheal administration, 2, 8 or 12 h prior to LPS inhalation Result:Prevented the accumulation of neutrophils in the BAL fluid. Significantly inhibited neutrophil accumulation when administered up to 8 h prior to LPS inhalation.
-
SynonymsRV568 | RV-568 | JNJ49095397
-
PathwayMAPK/ERK Signaling
-
Targetp38 MAPK
-
Recptorp38 MAPK
-
Research AreaInflammation/Immunology
-
IndicationCOPD
Chemical Information
-
CAS Number1220626-82-3
-
Formula Weight592.7
-
Molecular FormulaC34H36N6O4
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (168.72 mM)
-
SMILESCC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C4=CC=CC=C43)OCC5=CC(=NC=C5)NC(=O)COC
-
Chemical NameN-(4-((4-(3-(3-tert-Butyl-1-p-tolyl-1H-pyrazol-5-yl)ureido)-naphthalen-1-yloxy)methyl)yridin-2-yl)-2-methoxyacetamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Onions ST, et al. J Med Chem. 2016 Mar 10;59(5):1727-46.
2. Charron CE, et al. Eur Respir J. 2017 Oct 26;50(4). pii: 1700188.
molnova catalog
related products
-
Kamebakaurine
Kamebakaurin has the ability to protect the liver from APAP-induced hepatotoxicity, presumably by both inhibiting the inflammatory response and oxidative stress.
-
JNJ-49095397
JNJ-49095397 (RV-568) is a specific narrow-spectrum kinase inhibitor that inhibits a selected set of kinases involved in COPD inflammation with IC50 of 5, 40 and 52 nM for p38α, p38γ and HCK, respectively.
-
FPH2
FPH2 (BRD-9424) is a small molecule promoting differentiation of iPS-derived hepatocytes.
Cart
sales@molnova.com